Prospective evaluation of efficacy and safety of argon plasma coagulation therapy with submucosal injection prior to ablation in Barrett's esophagus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00003369

Enrollment

120

Registered

2011-11-29

Start date

2011-05-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C15.5

Interventions

Group 1: only one intervention arm in this arm, APC of Barrett's esophagus is carried out after prior submucosal injection

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: residual non-neoplastic Barrett's mucosa in the distal esophagus of at least 1 cm extent longitudinally or radially. Informed consent.

Exclusion criteria

Exclusion criteria: poor healing after previous endoscopic therapy, such as endoscopic resection; relevant comorbidity; other exclusion criteria such as pregnancy, age below 18 years, coagulation disturbances, renal insufficiency

Design outcomes

Primary

Measure	Time frame
Complete ablation of Barrett's mucosa by means of injection APC after Endoscopic Resection of early Barrett's cancer. The efficacy of APC is measured macroscopically and histologically; the latter by means of four-quadrant biopsies out of the previous Barrett's segment. Patients will be recruited until the end of July 2012. Eight weeks after complete Barrett's ablation, check-up upper gastrointestinal endoscopy is carried out.	—

Measure

Time frame

Complete ablation of Barrett's mucosa by means of injection APC after Endoscopic Resection of early Barrett's cancer. The efficacy of APC is measured macroscopically and histologically; the latter by means of four-quadrant biopsies out of the previous Barrett's segment. Patients will be recruited until the end of July 2012. Eight weeks after complete Barrett's ablation, check-up upper gastrointestinal endoscopy is carried out.

—

Secondary

Measure	Time frame
Safety of injection APC: The side effects of APC are documented in a specially designed prospective data sheet.	—

Countries

Germany

Contacts

Public ContactHendrik Manner

HSK Wiesbaden, Innere Medizin II

hendrik.manner@hsk-wiesbaden.de+611432420

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 17, 2026